Broman, Kristy K.
Bettampadi, Deepti
Pérez-Morales, Jaileene
Sun, James
Kirichenko, Dennis
Carr, Michael J.
Eroglu, Zeynep
Tarhini, Ahmad A.
Khushalani, Nikhil
Schabath, Matthew B.
Sarnaik, Amod
Sondak, Vernon K.
Zager, Jonathan S.
Funding for this research was provided by:
H. Lee Moffitt Cancer Center and Research Institute (Junior Scientist Research Partnership)
Article History
Received: 21 April 2021
Accepted: 24 June 2021
First Online: 6 August 2021
Disclosure
: Zeynep Eroglu served on the advisory boards of Array Biopharma, Regeneron, OncoSec, Genentech, Novartis, SunPharma, and Natera, and receives research funding from Novartis. Ahmad A. Tarhini has received fees for consulting and/or advisory board participation from Partner Therapeutics, Merck, Bristol Myers Squibb, Novartis, Genentech-Roche, Array Biopharma, Sanofi-Genzyme/Regeneron, Pfizer, EMD Serono, NewLink Genetics, BioNTech, Immunocore, and Eisai; has participated in a Data Safety Monitoring Board for Incyte; and has been involved in institution contracted research with Merck, OncoSec, Genentech-Roche, Bristol Myers Squibb, and Clinigen within the last 3 years. Nikhil Khushalani has received personal fees from Regeneron, Inc./Sanofi, Array BioPharma, AstraZeneca, EMD Serono, Genentech, Immunocore, Incyte, Jounce Therapeutics Merck, and Sanofi. He has received research grants and personal fees from Amgen, Gelgene, GlaxoSmithKline, Novartis, and Regeneron, and has received stock or other ownership interest from Amarin Corporation, Bellicum Pharmaceuticals, Mazor Robotics, and TransEnterix. Amod Sarnaik is a consultant to Iovance Biotherapeutics, Guidepoint, Defined Health, and Gerson Lehman group. His institution has received research funding from Iovance Biotherapeutics and Provectus Inc., and he has received speaker fees from Physicians’ Education Resource and Medscape. Vernon K. Sondak is a paid consultant to Merck, Bristol Myers Squibb, Novartis, Regeneron, Array, Replimune, Pfizer, Genentech/Roche, Eisai, Aduro, Amgen, TRM Oncology, and Polynoma. Jonathan S. Zager has received research funding from Novartis, Philogen, Delcath Systems, Amgen, Provectus, Novartis and Castle Biosciences. He has served on advisory boards for Merck, Novartis and Pfizer, and on the speakers bureau for Pfizer, Sun Pharma, and Castle Biosciences. He also provides expert testimony to McGowan Hood and Bubalo Law. Kristy K. Broman, Deepti Bettampadi, Jaileene Pérez-Morales, James Sun, Dennis Kirichenko, Michael J. Carr, and Matthew B. Schabath reported no disclosures.